Invivyd down 18% despite Pemgarda COVID risk reduction data08/28/2024 matejmo/E+ by way of Getty Images Patients handled with Invivyd’s (NASDAQ:IVVD) Pemgarda (pemivibart) confirmed an 84% relative risk reduction in symptomatic COVID-19 in comparison with placebo…
